53 2 SEGMENTAL INFORMATION A TURNOVER The Groups turnover comprises product sales, licence fees, contract research fees and milestone payments.
One customer, the CDC, accounted for 88%, 95% and 64% of Group turnover in 2003, 2002 and 2001 respectively.
The Directors are of the opinion that the Group has only one class of business.
The geographical analysis of turnover by origin and customer location, profit loss on ordinary activities before taxation and net assets liabilities.
Europe North America 2003 2002 2001 2003 2002 2001 m m m m m m Turnover by customer location 14.1 0.8 0.1 155.0 78.9 8.8 Turnover by origin 14.1 0.8 0.1 155.0 78.9 8.8 Profit loss on ordinary activities before taxation 0.9 2.7 0.6 40.3 12.3 13.1 Net assets liabilities 80.5 53.6 55.8 6.4 7.3 28.1 In 2003, sales to Europe represented 8% and sales to North America represented 92% of total sales.
Profit loss on ordinary activities before taxation in 2003 includes an exceptional item of 7.4m see note 4, of which 5.3m is included within Europe and 2.1m is included within North America.
3ADMINISTRATIVE COSTS 2003 2002 2001 m m m Administrative costs 3.2 3.1 2.3 Exceptional administrative item: settlement of BTG agreement see note 4 7.4 Amortisation of goodwill 1.5 1.2 1.2 Total administrative costs 12.1 4.3 3.5 4 EXCEPTIONAL ITEM In October 2003, the Group reached a settlement with BTG International Limited BTG concerning payments related to a technology licence originally established in 1994.
Under the agreement, the Group was required to pay 2% of its reported turnover to BTG, potentially until 2024.
Under the terms of the settlement, the Group paid 12m to BTG to discharge all past and future rights, obligations and claims under the agreement.
Of the settlement payment, 4.6m related to historical amounts due and payable under the agreement from January 2002 to 30 September 2003.
The balance of 7.4m related to potential future payments from the fourth quarter of 2003 onwards and as such has been charged as an exceptional item against operating profit in 2003.
5 AMOUNTS RELEASED PROVIDED AGAINST FIXED ASSET INVESTMENT In accordance with the Companies Act 1985, during the year, a previous write down was reversed on the investment of shares held in Medivir AB, which were acquired in 2000 in exchange for the assets of Mimetrix Limited.
This resulted in a gain of 0.5m 2002 loss of 0.1m.
6 INTEREST PAYABLE AND SIMILAR CHARGES TM This note details the interest payable on the ARILVAX overdraft facility see note 19 for more information, as well as interest payable in respect of assets held under finance leases and the unwinding of discounts on committed and potential future payments in respect of the acquisition of Berna Products Corporation.
2003 2002 2001 m m m On bank overdrafts 0.1 0.1 0.2 Interest element of finance leases 0.8 1.1 B Unwinding of discounts in relation to contingent and deferred consideration see note 15 0.1 1.0 1.2 0.2 B UNWINDING OF DISCOUNTS IN RELATION TO CONTINGENT AND DEFERRED CONSIDERATION IN AUGUST 2003 WE ANNOUNCED THE ACQUISITION OF BPC OF THOSE POTENTIAL FUTURE PAYMENTS AMOUNT TO SEE NOTE 15.
UNDER THE TERMS OF THE AGREEMENT, WE C. 2.9M $5.2M.
THE DIFFERENCE OF C. 0.5M $0.8M, ARE OBLIGED TO PAY UP TO A TOTAL OF C. 7.4M $12.5M FOR OF WHICH 0.1M $0.1M HAS BEEN CHARGED IN 2003, THAT BUSINESS.
OF THAT TOTAL, C. 3.4M $6.0M REPRESENTS WILL BE UNWOUND TO THE PROFIT AND LOSS ACCOUNT THE POTENTIAL CASH PAYMENT OF DEFERRED AND OVER THE PERIOD TO CRYSTALISATION OF THOSE PAYMENTS.
